Journal: Scientific Reports

Article Title: Retention of embryonic positional identity signatures in the adult sheep tail: evidence from HOXB13 spatial RNA expression gradients

doi: 10.1038/s41598-026-42438-7

Figure Lengend Snippet: Validation of RNA-seq–derived gene expression patterns in tail skin using TaqMan qPCR. (A) RNA-seq log2 fold-change values for selected differentially expressed genes ( HOXB13 , SP8 , ALOX15 , LOXL4 , AGT , HOXA13 , ACSM2B ) across three anatomical positions (tail base, mid-tail, tail tip) in rams with A/A and D/D HOXB13 genotypes. (B) TaqMan qPCR validation of gene expression profiles in tail skin for the same gene set and anatomical locations. Expression changes relative to the tail base are shown as log2 fold-changes. (C) TaqMan qPCR analysis of the same genes in tail bone tissue at the same anatomical positions. Patterns observed in bone samples closely mirrored those found in skin, especially for HOXB13 , HOXA13 , and ALOX15 . For all panels, mean expression changes are shown separately for A/A and D/D genotypes. Genes identified as up- or down-regulated in the RNA-seq data displayed concordant expression trends in qPCR validations.

Article Snippet: For the target genes, the following TaqMan Gene Expression Assays were used: ALOX15 (Oa04833777_m1), HOXA13 (Oa04668307_m1), ACSM2B (Oa04721289_m1), AGT (Oa04814695_m1), LOXL4 (Oa04673501_m1), and SP8 , which was custom-designed.

Techniques: Biomarker Discovery, RNA Sequencing, Derivative Assay, Gene Expression, Expressing

Journal: Molecular Therapy. Nucleic Acids

Article Title: A computational model-powered platform to inform the development of GalNAc-conjugated siRNA therapeutics

doi: 10.1016/j.omtn.2026.102936

Figure Lengend Snippet: A workflow of this study (A) Overview of the mechanism of action of N-acetylgalactosamine-small interfering RNA (GalNAc-siRNA) and the seven approved GalNAc-SiRNA drugs collected in this study. (B) Schematic structure of the developed computational model for a GalNAc-siRNA. (C) Schematic workflow of the model informed GalNAc-siRNA development powered by the established computational platform.

Article Snippet: Finally, the platform was utilized to support the development of an investigational new angiotensinogen ( AGT )-silencing GalNAc-siRNA, termed SAL0132 (developed by Shenzhen Salubris Pharmaceuticals Co., Ltd), from preclinic rats and monkey to clinical studies.

Techniques: Small Interfering RNA